Skip to main content

Advertisement

Table 1 Baseline characteristics according to pre-study DMD treatment (intent-to-treat population; n = 119)

From: Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

  Number (%) of patients Age, years Duration of MS, years EDSS score* PASAT score HADS Anxiety score HADS Depression score
Pre-study DMD   Median (range); 95% confidence interval
im IFN β-1a 75 (63.0) 39 5 2 42.5 7 5
   (19-58) (0-22) (0-5.5) (5-60) (0-20) (0-20)
   35.6, 39.9 4.9, 7.3 1.9, 2.4 40.0, 45.3 6.9, 9.2 4.9, 7.0
IFN β-1b 26 (21.8) 37 3.5 1.5 48 7 3.5
   (20-52) (0-22) (0-6) (24-59) (0-13) (0-15)
   34.1, 42.4 3.1, 8.6 1.3, 2.4 42.6, 50.8 5.0, 7.8 3.5, 7.1
Glatiramer acetate 15 (12.6) 41 4 1.5 35 7 3
   (18-55) (1-8) (0-4.5) (18-52) (0-14) (0-12)
   31.7, 44.5 2.7, 5.3 1.3, 2.9 30.5, 41.9 3.8, 9.0 2.3, 7.0
sc IFN β-1a 3 (2.5) 35 6 3 46 4 6
   (22-43) (6-11) (2-4) (25-51) (4-10) (2-6)
   7.0, 59.6 0.5, 14.8 0.5, 5.5 6.4, 74.9 -2.6, 14.6 -1.1, 10.4
  1. *Range: 0 (no disability) to 10 (severe disability resulting in death)
  2. Range: 0 to 60 (higher scores indicate better cognitive function)
  3. Range: 0 to 21 (higher scores indicate more severe symptoms)
  4. n = 72
  5. DMD disease-modifying drug, EDSS Expanded Disability Status Scale, HADS Hospital Anxiety and Depression Scale, IFN interferon, im intramuscular, MS multiple sclerosis, PASAT Paced Auditory Serial Addition Task, sc subcutaneous